News | May 17, 2022
Eight Roads announce US $ 250 million healthcare fund for India
This new fund is amongst the largest for the sector in India
This new fund is amongst the largest for the sector in India
Deucravacitinib is currently under regulatory review in multiple regions, including the U.S., Europe and Japan, and would be the first selective allosteric tyrosine kinase 2 (TYK2) inhibitor approved for the treatment of any disease
“We are committed to making India a global medical value hub by further strengthening our traditional medicine industry and boosting 'Heal in India' & 'Heal by India'
Company's net income rose by 57.5 percent to 3.291 billion euros in Q1
Novel approach driven by GN Corp Japan with potentials in neurological illnesses
Center of Excellence for Molecular Diagnostics and Proteomics will enable affordable diagnostics for infectious diseases in India
Ultomiris showed early effect and lasting improvement in activities of daily living and has potential to reduce treatment burden with dosing every 8 weeks
Business EPS of €1.94, up 20.5% on a reported basis and 16.1% at CER, also benefitting from an improved effective tax rate
This facility will design & develop instruments, perform product reliability performance testing and verification
Results support the development of tislelizumab in potentially synergistic combinations across Novartis advanced therapeutic platforms for the treatment of an array of solid tumours
Subscribe To Our Newsletter & Stay Updated
